A meta-analysis of 17 studies of patients with CRC and gastric cancer found an association of poor response in terms of PFS and OS to an oxaliplatin-based regimen for the ERCC1 rs11615C>T polymorphism in the T allele in Asians, as well as an association regarding PFS and OS in Caucasians for the rs13181T>G polymorphism in the G allele [45]. The gene discussed is ERCC1; the disease is colorectal carcinoma.